Abuse of tapentadol compared to other atypical opioids among individuals entering treatment for opioid use disorders
Journal of Opioid Management · 2023
DOI: 10.5055/jom.0818 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Opioid Management, 2023. Verfasst von S Geoff Severtson und 6 weiteren Autor:innen. Beteiligte Einrichtung: Rocky Mountain Poison & Drug Safety, Denver Health and Hospital Authority, Denver, Colorado. Hauptthemen laut MEDLINE: Tramadol, Opioid-Related Disorders, Buprenorphine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Abstract (Originalsprache)
Objective
Tapentadol is an atypical opioid analgesic thought to have dual mechanisms of action: μ-receptor agonism and inhibition of norepinephrine reuptake. Unlike other atypical opioids, tapentadol is a schedule II-controlled substance. We compared the prevalence of abuse (use to get high) of tapentadol to other atypical opioids used to treat pain (buprenorphine and tramadol).
Design
An observational, serial cross-sectional study.
Setting
Individuals enrolling in treatment programs for opioid use disorder in 2019. Each completed a self-administered, paper questionnaire assessing prescription drug abuse and illegal drug use within 1 week of enrollment. Main outcome measures: Indication of past month abuse of tapentadol or comparator drugs on a self-administered questionnaire.
Results
There were 6,987 respondents. Unadjusted and utilization-adjusted logistic regression models were used to compare odds of endorsement of tapentadol to tramadol and buprenorphine products indicated for the management of pain. Unadjusted abuse prevalence was 0.20 percent for total tapentadol (0.03 percent for NUCYNTA® and 0.06 percent for NUCYNTA ER). Relative to total tapentadol, the odds of abuse of buprenorphine for pain was 2.9 times greater (95 percent CI: 1.6 to 5.3, p < 0.001), and for tramadol, 43.1 times greater (95 percent CI: 25.3 to 73.3, p < 0.001). Adjusting for prescriptions dispensed, differences in odds of abuse were not statistically significant (odds ratio (OR) = 1.6, 95 percent CI: 0.9 to 3.0, p = 0.108 for buprenorphine for pain and OR = 0.7, 95 percent CI: 0.4 to 1.2, p = 0.209 for tramadol).
Conclusions
Tapentadol use to get high is less frequent than other atypical opioids. Findings suggest tapentadol is rarely the primary drug abused by an individual.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Rocky Mountain Poison & Drug Safety, Denver Health and Hospital Authority, Denver, Colorado.
- American Association for the Treatment of Opioid Dependence (AATOD), New York, New York.
- Department of Psychiatry, School of Medicine, Washington University in St. Louis, St. Louis, Missouri.
- Rocky Mountain Poison & Drug Safety, Denver Health and Hospital Authority, Denver; Department of Emergency Medicine, School of Medicine, University of Colorado, Aurora, Colorado.
Zitieren
APA
Severtson, S. G., Gurrola, M. C., Parrino, M. W., Ellis, M. S., Cicero, T. J., Iwanicki, J. L., & Dart, R. C. (2023). Abuse of tapentadol compared to other atypical opioids among individuals entering treatment for opioid use disorders. Journal of Opioid Management. https://doi.org/10.5055/jom.0818
Vancouver
Severtson SG, Gurrola MC, Parrino MW, Ellis MS, Cicero TJ, Iwanicki JL, et al. Abuse of tapentadol compared to other atypical opioids among individuals entering treatment for opioid use disorders. Journal of Opioid Management. 2023. doi:10.5055/jom.0818
BibTeX
@article{Severtson2023,
author = {Severtson, S Geoff and Gurrola, Marie C and Parrino, Mark W and Ellis, Matthew S and Cicero, Theodore J and Iwanicki, Janetta L and Dart, Richard C},
title = {Abuse of tapentadol compared to other atypical opioids among individuals entering treatment for opioid use disorders},
journal = {Journal of Opioid Management},
year = {2023},
doi = {10.5055/jom.0818}
}
EUVIMED